Celgene submits application to FDA for Ozanimod for treatment of relapsing forms of MS
Celgene announced the Company has submitted a New Drug Application to the FDA for ozanimod for treatment of adults with relapsing forms of multiple sclerosis. Ozanimod is an oral, sphingosine 1-phosphate receptor modulator, which binds with high affinity selectively to S1P subtypes 1 and 5. March 25, 2019